149 related articles for article (PubMed ID: 36803895)
1. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
Smits PD; Gratzl S; Simonov M; Nachimuthu SK; Goodwin Cartwright BM; Wang MD; Baker C; Rodriguez P; Bogiages M; Althouse BM; Stucky NL
Vaccine; 2023 Apr; 41(15):2447-2455. PubMed ID: 36803895
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization.
Stroffolini T; Ciancio A; Federico A; Benigno RG; Colloredo G; Lombardi A; Niro GA; Verucchi G; Ferrigno L; Gioli F; Marignani M
Dig Liver Dis; 2023 Mar; 55(3):316-321. PubMed ID: 36529636
[TBL] [Abstract][Full Text] [Related]
4. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021.
Wang L; Wang Q; Davis PB; Volkow ND; Xu R
World Psychiatry; 2022 Feb; 21(1):124-132. PubMed ID: 34612005
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital.
S M; Hr C
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443499
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.
Wang W; Kaelber DC; Xu R; Berger NA
JAMA Oncol; 2022 Jul; 8(7):1027-1034. PubMed ID: 35394485
[TBL] [Abstract][Full Text] [Related]
7. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
8. Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series.
Kim PS; Schildhouse RJ; Saint S; Bradley SF; Chensue S; Houchens N; Gupta A
Am J Infect Control; 2022 Mar; 50(3):273-276. PubMed ID: 34653528
[TBL] [Abstract][Full Text] [Related]
9. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.
Brosh-Nissimov T; Orenbuch-Harroch E; Chowers M; Elbaz M; Nesher L; Stein M; Maor Y; Cohen R; Hussein K; Weinberger M; Zimhony O; Chazan B; Najjar R; Zayyad H; Rahav G; Wiener-Well Y
Clin Microbiol Infect; 2021 Nov; 27(11):1652-1657. PubMed ID: 34245907
[TBL] [Abstract][Full Text] [Related]
10. High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection.
Heinzl MW; Kolenchery L; Resl M; Klammer C; Black A; Obendorf F; Schinagl L; Feldbauer R; Pohlhammer J; Wagner T; Berger T; Dieplinger B; Clodi M
Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497655
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
Bierle DM; Ganesh R; Tulledge-Scheitel S; Hanson SN; Arndt LL; Wilker CG; Razonable RR
J Infect Dis; 2022 Feb; 225(4):598-602. PubMed ID: 34791298
[TBL] [Abstract][Full Text] [Related]
12. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.
Butt AA; Yan P; Shaikh OS; Mayr FB; Omer SB
Clin Infect Dis; 2022 Aug; 75(1):e849-e856. PubMed ID: 34893812
[TBL] [Abstract][Full Text] [Related]
13. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates.
Dash NR; Barqawi HJ; Obaideen AA; Al Chame HQ; Samara KA; Qadri R; Eldesouki S
J Epidemiol Glob Health; 2023 Mar; 13(1):67-90. PubMed ID: 36795274
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
Darby B; Alexander V; Murphy J
Vaccine; 2023 Feb; 41(7):1295-1298. PubMed ID: 36690560
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA
JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems.
Hogarth M; John D; Li Y; Wang-Rodriguez J; Chakladar J; Li WT; Mehta SR; Jain S; Ongkeko WM
Am J Med Sci; 2023 Aug; 366(2):102-113. PubMed ID: 37146904
[TBL] [Abstract][Full Text] [Related]
19. Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults.
Nishimi K; Neylan TC; Bertenthal D; Seal KH; O'Donovan A
JAMA Netw Open; 2022 Apr; 5(4):e227287. PubMed ID: 35420660
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US.
Lang R; Humes E; Coburn SB; Horberg MA; Fathi LF; Watson E; Jefferson CR; Park LS; Gordon KS; Akgün KM; Justice AC; Napravnik S; Edwards JK; Browne LE; Agil DM; Silverberg MJ; Skarbinski J; Leyden WA; Stewart C; Hogan BC; Gebo KA; Marconi VC; Williams CF; Althoff KN;
JAMA Netw Open; 2022 Oct; 5(10):e2236397. PubMed ID: 36227594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
